This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Jeffrey A. Lieberman, MD; John M. Kane, MD; Stavros Sarantakos, MD; Dominick Gadaleta, MD; Margaret Woerner, PhD; Jose Alvir, DrPH; Jorge Ramos-Lorenzi, MD
Department of Psychiatry Hillside Hospital Long Island Jewish Medical Center PO Box 38 Glen Oaks, NY 11004

Arch Gen Psychiatry. 1989;46(4):387.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

Chandler suggests that neuroleptic discontinuation studies in patients with schizophrenia are unethical. Though this point of view is understandable, we believe it is not warranted and does not reflect a comprehensive understanding of the relevant issues. The efficacy of neuroleptics in schizophrenia is proved but is limited by several factors, perhaps most significantly by the capacity of neuroleptics to cause tardive dyskinesia. In addition, there is marked variability in the course of illness among schizophrenic patients.¹ This is evident in the maintenance treatment literature, which shows that many patients (approximately 30%) relapse despite receiving neuroleptic medication, while neuroleptics can be withdrawn from other patients for many months and in some cases for years without relapse.^2,3 Standard maintenance medication treatment strategies, though they are indisputably effective in group comparisons, may be quite inefficient in addressing the treatment requirements of the individual patient. This has prompted the targeted . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?